Table 3 Multivariate Cox regression models for combined NB validation cohorts based on OS considering single prognostic marker and the 18-gene Stage4 NB risk score
From: An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma
Marker | Hazard ratio | 95Â % CI | P value |
|---|---|---|---|
Validation cohort 1 + 2 (n = 241) | |||
Age (≥18 vs < 18 months) | 2.64 | 1.579–4.414 | 0.00020 |
MYCN (amplified vs not amplified) | 2.549 | 1.744–3.727 | 0.000001 |
18-gene Stage 4 NB risk score (high vs low risk score groups) | 2.237 | 1.098–4.554 | 0.027 |